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Loss-of-function mutations in hematopoietic transcription factors including PAX5 occur in most cases of
B-progenitor acute lymphoblastic leukemia (B-ALL), a disease characterized by the accumulation of undifferen-
tiated lymphoblasts. Although PAX5 mutation is a critical driver of B-ALL development in mice and humans,
it remains unclear how its loss contributes to leukemogenesis and whether ongoing PAX5 deficiency is required
for B-ALL maintenance. Here we used transgenic RNAi to reversibly suppress endogenous Pax5 expression in
the hematopoietic compartment of mice, which cooperates with activated signal transducer and activator of
transcription 5 (STAT5) to induce B-ALL. In this model, restoring endogenous Pax5 expression in established
B-ALL triggers immunophenotypic maturation and durable disease remission by engaging a transcriptional
program reminiscent of normal B-cell differentiation. Notably, even brief Pax5 restoration in B-ALL cells
causes rapid cell cycle exit and disables their leukemia-initiating capacity. These and similar findings in human
B-ALL cell lines establish that Pax5 hypomorphism promotes B-ALL self-renewal by impairing a differentiation
program that can be re-engaged despite the presence of additional oncogenic lesions. Our results establish
a causal relationship between the hallmark genetic and phenotypic features of B-ALL and suggest that engaging
the latent differentiation potential of B-ALL cells may provide new therapeutic entry points.
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Acute lymphoblastic leukemia (ALL) is the most common
pediatric cancer, and despite cure rates approaching 90%,
it remains a leading cause of childhood morbidity and
mortality in developed countries (Inaba et al. 2013). Most
ALL cases involve transformation of B-cell progenitors at
the highly proliferative pre-B-cell stage of differentiation
(B-ALL). B-ALL subtypes have traditionally been defined
by recurrent cytogenetic abnormalities, including chro-
mosome translocations encoding the fusion oncoproteins
ETV6-RUNX1 (TEL-AML1) or breakpoint cluster region
(BCR)-ABL1. However, in recent years, our understanding
of the genetic basis of ALL has been revolutionized by
high-resolution genome-wide studies of large ALL cohorts,
which have identified recurrent submicroscopic genetic
alterations influencing leukemia onset and therapy
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response (Inaba et al. 2013). Remarkably, loss-of-function
mutations or focal deletions in genes encoding transcrip-
tional regulators of lymphoid development, including
PAX5, IKZF1, TCF3, and EBF1, occur in approximately
two-thirds of B-ALL cases (Mullighan et al. 2007; Inaba et al.
2013). Most common among these is PAX5, with mono-
allelic deletions, fusion translocations, or point muta-
tions that disrupt PAX5 DNA-binding or transcriptional
regulatory functions occurring in approximately one-third
of B-ALLs (Kuiper et al. 2007; Mullighan et al. 2007).
Somatic PAX5 alterations occur in up to 50% of the
high-risk BCR-ABL1-positive and Ph-like ALL subtypes
(Mullighan et al. 2008; Roberts et al. 2012) and are also
acquired during progression of chronic myeloid leukemia
(CML) to lymphoid blast crisis (Mullighan et al. 2008).
Germline hypomorphic mutations in PAX5 have recently
been associatedwith B-ALL susceptibility (Shah et al. 2013).
In mice, Pax5 acts downstream from the essential
B-lineage transcription factors Tcf3 (E2A) and Ebf1 to
commit lymphoid progenitors to a B-cell fate (Cobaleda
et al. 2007; Nutt and Kee 2007). B-cell development in
Pax5-deficient mice is arrested at the early pro-B-cell
stage in the bonemarrow (Nutt et al. 1997), and Pax5-null
pro-B cells can differentiate into multiple non-B-cell
hematopoietic lineages in vitro and in vivo (Nutt et al.
1999; Rolink et al. 1999; Schaniel et al. 2002). Pax5 drives
B-lineage commitment by transcriptionally activating
B-lineage-specific gene expression networks while repres-
sing alternative lineage genes and remains essential in
mature B-lineage cells (Cobaleda et al. 2007).
A conserved tumor suppressor role for Pax5was recently
demonstrated in a transgenic B-ALL mouse model driven
by hematopoietic expression of a constitutively active
form of signal transducer and activator of transcription 5
(STAT5), which is activated downstream from several
human B-ALL oncogenes, including BCR-ABL1, activated
JAK kinases, and activated IL7R (Malin et al. 2010). These
STAT5b-CAmicenormally develop B-ALLwith a relatively
long latency and low penetrance (Burchill et al. 2003;
Nakayama et al. 2008), but this is dramatically accelerated
by Pax5 heterozygosity (Heltemes-Harris et al. 2011).
Tumors arising in STAT5b-CA;Pax5+/ mice invariably
retain the wild-type Pax5 allele (Heltemes-Harris et al.
2011), consistent with mutations in human B-ALL that
reduce rather than ablate PAX5 function (Mullighan et al.
2007; Shah et al. 2013).
Although these studies clearly define PAX5 and related
transcription factors as B-ALL tumor suppressors, the
critical question of how their loss contributes to leuke-
mogenesis remains unexplored. It has been postulated
that these transcription factor mutations are involved in
the differentiation block characteristic of B-ALL; how-
ever, experimental evidence supporting this concept is
lacking.Moreover, it remains unclear whether inactivating
mutations in transcriptional regulators of B-cell develop-
ment promote leukemogenesis by simply creating an
aberrant progenitor compartment that is susceptible to
malignant transformation through accumulation of sec-
ondary mutations or whether they retain driver functions
in established leukemia. Understanding whether these
hallmark mutations are required for B-ALL maintenance
provides important rationale for therapeutic strategies
targeting their downstream effectors. To directly address
these questions, we developed a transgenic RNAi-based
B-ALL mouse model allowing inducible suppression and
restoration of endogenous Pax5 expression in vivo and
used it to define leukemogenic mechanisms and transcrip-
tional programs imposed by hypomorphic Pax5 states in
leukemia. We demonstrate that restoration of Pax5 re-
engages B-lineage differentiation, leading to progressive
tumor clearance and long-term survival.
Results
Stable Pax5 knockdown disrupts B-cell development
in vivo
Hypomorphic PAX5 mutations are a common feature of
B-ALL (Mullighan et al. 2007; Shah et al. 2013). To model
this in mice, we generated several retroviral vectors encod-
ing microRNA-based shRNAs that effectively inhibited
Pax5 protein expression in a mouse B-cell line in vitro
(Fig. 1A). To examine the effects of stable Pax5 knock-
down in vivo, we reconstituted lethally irradiated re-
cipient mice with fetal liver-derived hematopoietic
stem and progenitor cells transduced with effective
LMP-shPax5 vectors that stably coexpress green fluores-
cent protein (GFP). Flow cytometry showed normal pro-
portions of CD19+ B-lineage cells in spleens of mice
reconstituted with cells transduced with control shRNAs
targeting firefly luciferase (shLuc) but a decreased pro-
portion of GFP+ B-lineage cells in shPax5-reconstituted
mice (Fig. 1B,C). In this context, GFP intensity reports
multiplicity of infection; therefore, an inverse correlation
between shPax5 (GFP) expression and CD19 expression
suggests that B-lineage development is Pax5 dose-depen-
dent in vivo (Fig. 1B,C). These data demonstrate that
shRNA-mediated Pax5 inhibition disrupts normal B-cell
development in vivo, in keeping with observations in
Pax5-null mice (Nutt et al. 1999).
Reversible Pax5 knockdown in transgenic mice
To reversibly manipulate endogenous Pax5 expression in
vivo, we generated transgenic mice allowing tetracycline
(tet)-regulated Pax5 knockdown. Tet-regulated RNAi com-
prises three components: a tet-responsive element (TRE)
promoter driving shRNA expression, a tet transactivator
that conditionally activates the TRE promoter, and doxy-
cycline (Dox), which reversibly controls transactivator
function. Dox inhibits the tTA (tet-off) transactivator,
whereas the rtTA (tet-on) transactivator is Dox-dependent.
Using a recently established strategy (Premsrirut et al.
2011), we produced transgenic mice in which a TRE
promoter targeted to the type I collagen (Col1a1) locus
controls coexpression of GFP and the effective Pax5.437
shRNA. We crossed TRE-GFP-shPax5 mice with Vav-tTA
transgenic mice, which have pan-hematopoietic expres-
sion of tTA (Kim et al. 2007; Takiguchi et al. 2013).
Consistent with our retroviral Pax5 knockdown ex-
periments, the proportion of B-lineage cells within the
Liu et al.
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GFP+ cell population in the blood, spleen, and bone
marrow of Vav-tTA;TRE-GFP-shPax5 bitransgenic mice
was reduced relative to control mice expressing an
shRNA targeting Renilla luciferase (shRen) (Fig. 2A,B).
Analysis of B-lineage development in the bone marrow
revealed an increase in the proportion of pro-B cells and
a decreased proportion of immature and recirculating B
cells within the GFP+ cell population of Vav-tTA;TRE-
GFP-shPax5 bitransgenic mice (Fig. 2C), and shPax5-
expressing B-cell progenitors had reduced Pax5 protein
expression (Fig. 2D). These data verify that transgenic, tet-
regulatable Pax5 knockdown inhibits Pax5 expression and
blocks B-lineage differentiation in vivo.
Pax5 knockdown cooperates with constitutively active
STAT5 in leukemogenesis
Germline Pax5 heterozygosity accelerates leukemogene-
sis in a mouse model of B-ALL driven by transgenic
expression of constitutively active STAT5 (Heltemes-
Harris et al. 2011). To reproduce this genetic interaction
using RNAi-based Pax5 inhibition, we generated STAT5b-
CA;Vav-tTA;TRE-GFP-shPax5 tritransgenic mice along
with littermate STAT5b-CA single- and bitransgenic
controls. Tritransgenic mice developed fully penetrant
B-ALL with a median latency of 146 d, compared with
partially penetrant disease in control mice with a median
latency of 345 d (P < 0.0001, log rank test) (Fig. 3A).
Consistent with previous findings in STAT5b-CA;Pax5+/
mice (Heltemes-Harris et al. 2011), most tritransgenic
leukemias were B220+KitCD19+CD25+ and negative for
surface IgM, indicating a differentiation block at the pre-
B-cell stage, with GFP expression indicating that Pax5
knockdown contributed to leukemogenesis (Fig. 3B,C;
Supplemental Table S1). RNA sequencing (RNA-seq)
of the leukemia from a representative primary tritrans-
genic mouse revealed monoclonal rearrangement of the
immunoglobulin heavy chain (Igh) locus (Supplemental
Fig. S1). These findings suggest that additional cooper-
ating genetic changes likely contribute to leukemogen-
esis in this model.
Pax5 restoration causes B-ALL regression
To restore Pax5 expression in established leukemias in
vivo, we initially transplanted leukemia cells from rep-
resentative tritransgenic mouse A024 into cohorts of
Rag1/mice. Recipient mice developed aggressive GFP+
leukemia within 2–3 wk, with very high peripheral white
blood cell (WBC) counts (Fig. 3D,E), palpable splenomeg-
aly, and enlarged lymph nodes. As anticipated, Dox
treatment of mice with a significant peripheral tumor
burden caused a progressive decrease in GFP fluorescence
intensity of circulating leukemia cells, indicating shutoff
of the TRE-GFP-shPax5 transgene (Fig. 3F; see below).
Whereas untreated leukemic mice succumbed to disease
within 1 wk, the condition of Dox-treated mice markedly
improved, and, after 18 d, their WBC counts had almost
normalized (Fig. 3D,E). Tumor regression brought about
by continuous Dox treatment consistently extended host
life span, with mice surviving for many weeks without
overt signs of leukemia (Fig. 3G). Tumor growth in mice
bearing control STAT5b-CA or STAT5b-CA;Pax5+/ leu-
kemiaswas unabated uponDox treatment (data not shown),
ruling out nonspecific effects. These results demonstrate
that ongoing Pax5 suppression is required for B-ALL
maintenance in vivo.
Pax5 restoration releases the pre-B stage
differentiation block in B-ALL
Having observed tumor regression upon sustained Dox
treatment, we monitored leukemia clearance kinetics
in several diseased mice using flow cytometry of periph-
eral blood at 3-d intervals following Dox administra-
tion. Transplanted leukemias recapitulated the primary
CD19+KitCD25+IgM pre-B stage disease; therefore,
CD19 flow cytometry readily identified leukemia cells
in the blood of lymphocyte-deficient Rag1/ recipient
mice (Fig. 4A–C). Remarkably, the proportion of leukemia
Figure 1. Pax5 knockdown inhibits B-cell differentiation in
vivo. (A) Western blot of Pax5 expression in WEHI-231 B lym-
phoma cells transduced with LMP-shPax5 vectors, with num-
bers indicating different shRNAs. NIH3T3 fibroblasts are included
as a Pax5-negative control, and histone H3 is shown as a loading
control. (B) Flow cytometric analysis of GFP expression in
splenocytes from representative mice reconstituted with fetal
liver hematopoietic stem and progenitor cells transduced with
LMP-shPax5 and control LMP-shLuc vectors. Mice were ana-
lyzed 12 wk following reconstitution. B-lineage cells are
identified by surface CD19 expression. (C) Relative proportions
of B-lineage cells in the spleen using GFP gating as indicated in
B. Mean 6 SEM; n = 3 for shLuc; n = 4 for shPax5.
Reversible differentiation block in B-ALL
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cells in the blood of Dox-treated mice decreased incre-
mentally from day 3 onward, falling to ;10% at day 18,
indicating that Pax5 restoration results in gradual leuke-
mia clearance rather than acute regression (Fig. 4B–D).
During normal B-cell development in the bonemarrow,
productive Igh gene rearrangement results in pre-B-cell
receptor (pre-BCR) assembly and signaling in pre-B cells,
triggering their clonal expansion (Rolink et al. 2000). These
‘‘large cycling’’ pre-B cells (also known as large pre-BII cells
[Rolink et al. 1994] or fraction C9 cells [Hardy et al. 1991])
then exit the cell cycle to become ‘‘small resting’’ pre-B
cells (small pre-BII or fraction D cells), whereupon pro-
ductive rearrangement of the immunoglobulin light
chain genes Igk or Igl allows the surface IgM expression
characteristic of immature B cells. Notably, Dox treat-
ment of leukemic mice resulted in expression of IgM in an
increasing proportion of circulating CD19+ leukemia cells
over time (Fig. 4B,C,E). Indeed, after 15 d, when tumor
burden had significantly decreased, ;80% of cells were
IgM+. The kinetics of IgM acquisition varied between
individual leukemic mice but occurred in the majority of
CD19+ cells within a 3-d period during Dox treatment (Fig.
4B,C). Similar effects were seen in mice transplanted with
independent tritransgenic leukemia A008, although this
leukemia showed a more striking immunophenotypic
maturation after ;10 d on Dox, with the majority of
antecedent leukemia cells coexpressing the mature
marker IgD along with IgM (Supplemental Fig. S2A–F).
Together, these data suggest that re-engaging endogenous
Pax5 function releases the pre-B-cell stage differentiation
block in leukemia, promoting Igk or Igl recombination and
IgM expression characteristic of mature B cells.
The bone marrow and spleen of mice bearing leukemia
A024 was dominated by CD19+ leukemia cells coexpress-
ing the immature marker CD93, which is normally
expressed by pro-B, pre-B, and immature B cells in the
bone marrow and by immature transitional B cells in the
spleen (Fig. 4F). Nine days of Dox treatment led to down-
regulation of CD93 expression on a substantial propor-
tion of CD19+ cells in the bone marrow and spleen,
indicating maturation of antecedent leukemia cells in
these organs (Fig. 4F). This was accompanied by surface
IgM expression in a significant proportion of cells (Fig. 4G).
Consistent with changes in peripheral leukemia burden,
flow cytometry analysis demonstrated near-complete
clearance of leukemia cells from the bone marrow and
spleen following 18 d of Dox treatment (Fig. 4F,G).
Although continuous Dox treatment caused leukemia
regression and extended host life span (Fig. 3G), after
many weeks, mice becamemoribund, with splenomegaly
and enlarged lymph nodes. Unexpectedly, in all mice
examined, these organs were mainly comprised of host-
derived cells, potentially expanded in response to ante-
cedent leukemia cells (Supplemental Fig. S3). In contrast,
while sustained Pax5 restoration in independent tritrans-
genic leukemia A008 caused similar acute regression and
robust differentiation, in this case, mature leukemia-
derived cells accumulated in lymph nodes and spleens
Figure 2. Tet-regulated Pax5 knockdown in transgenic mice in vivo. (A) Flow cytometry analysis of expression of the B-lineage marker
CD19 and GFP in the peripheral blood, spleen, and bone marrow of representative Vav-tTA;TRE-GFP-shRen and Vav-tTA;TRE-GFP-
shPax5 mice. (B) Decreased proportion of GFP+ B cells in the peripheral blood (P < 0.05, Student’s t-test), spleen (P < 0.01), and bone
marrow (P < 0.05) of Vav-tTA;TRE-GFP-shPax5mice relative to Vav-tTA;TRE-GFP-shRenmice (mean 6 SEM; n = 3 for each group). (C)
Analysis of GFP+CD19+ B lineage cells in the bone marrow of Vav-tTA;TRE-GFP-shRen and Vav-tTA;TRE-GFP-shPax5 mice (mean 6
SEM; n = 3 for each group). Relative to controls, Vav-tTA;TRE-GFP-shPax5mice have an increased proportion of pro-B cells (Kit+CD25
IgM; P < 0.001), similar pre-B cells (KitCD25+ IgM), and fewer immature and recirculating mature B cells (IgM+IgD and IgM+IgD+,
respectively; both P < 0.001). (D) Western blot of Pax5 expression in GFP+ pre-B and immature B cells isolated from the bone marrow of
representative Vav-tTA;TRE-GFP-shRen and Vav-tTA;TRE-GFP-shPax5 mice, with histone H3 as a loading control.
Liu et al.
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of all mice analyzed after 2 wk on Dox (Supplemental Fig.
S2G,H). In summary, although long-term Dox responses
of individual primary leukemias varied (Supplemental
Table S1), potentially due to different genetic changes
during leukemogenesis, Pax5 restoration in pre-B-cell
leukemias uniformly caused acute tumor clearance and/
or differentiation in vivo.
Identification of Pax5-regulated genes in B-ALL
Expression profiling of Pax5-deficient mice has identified
Pax5-regulated genes in normal pro-B and mature B cells
(Delogu et al. 2006; Schebesta et al. 2007; Pridans et al.
2008; Revilla-I-Domingo et al. 2012); however, Pax5-
regulated genes in pre-B-ALL remain poorly defined. To
identify transcriptional responses to acute Pax5 restora-
tion in leukemias in vivo, STAT5b-CA;Vav-tTA;TRE-
GFP-shPax5 leukemia cells were isolated by FACS from
the bone marrow of triplicate, transplanted leukemic
mice that were either untreated or Dox-treated for 3 d
(GFPhigh and GFPmid cells, respectively) (Fig. 3F). Al-
though the leukemia immunophenotype was stable dur-
ing these initial stages of Pax5 restoration (Fig. 4), we
reasoned that expression profiling at this point would
enrich for primary Pax5-dependent gene expression
changes. RNA-seq revealed that leukemia cells from
untreated mice expressed Pax5 mRNA at levels ;40%
of those in normal bone marrow CD19+KitCD25+IgM
Figure 3. Transgenic Pax5 knockdown promotes reversible B-ALL development. (A) Kaplan-Meier survival curve of STAT5-CA;Vav-
tTA;TRE-GFP-shPax5 mice (purple line; n = 16) relative to pooled littermate controls (STAT5-CA mice, STAT5-CA;Vav-tTA mice, and
STAT5-CA;TRE-GFP-shPax5 mice; red line; n = 15). Vav-tTA;TRE-GFP-shPax5 control mice (blue line; n = 7) are also shown. (B)
Immunophenotype of bone marrow (top panels) and blood (bottom panels) cells from a representative STAT5-CA;Vav-tTA;TRE-GFP-
shPax5 leukemic mouse A024 showing B220 and IgM expression (left panels), CD25 expression on B220+IgM cells (middle panels), and
GFP expression in CD25+Kit cells (right panels). (C) Summary of leukemic tritransgenic mouse phenotypes. (D) Blood smears from
representative Rag1/ mice transplanted with STAT5-CA;Vav-tTA;TRE-GFP-shPax5 leukemia A024 either untreated or with Dox
administered at leukemia onset as indicated. (E) Peripheral white (WBC) and red (RBC) blood cell counts from mice as shown in
D. Counts from control untransplanted Rag1/mice are included. Mean 6 SEM; n = 3 for each group; P < 0.05 for WBC (untreated vs.
18d Dox), Student’s t-test. (F) Histogram of GFP expression in CD19+ leukemia cells in the peripheral blood of mice transplanted with
STAT5-CA;Vav-tTA;TRE-GFP-shPax5 leukemia cells and Dox-treated as indicated. (G) Kaplan-Meier survival curve for Rag1/ mice
transplanted with STAT5-CA;Vav-tTA;TRE-GFP-shPax5 leukemia. Dox treatment of leukemic mice was initiated at day 0. n = 5
untreated mice and Dox-treated mice; log rank test, P < 0.005.
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pre-B cells, which aremainly small resting pre-B cells (Fig.
5A; Hoffmann et al. 2002). Three days of Dox treatment
effectively restored Pax5mRNA to near wild-type levels,
with a corresponding increase in protein expression
(Fig. 5A,B). Surprisingly, this was accompanied by signif-
icant up-regulation of 3343 genes and down-regulation of
3240 genes (false discovery rate [FDR] 0.05), together
comprising more than half of the expressed genes in
Figure 4. Pax5 restoration triggers leukemia differentiation and regression. (A) Flow cytometry of CD19 and IgM expression in peripheral
blood of wild-type (top panel) and untransplanted Rag1/ (bottom panel) control mice. (B) Flow cytometry of CD19 and IgM expression
on mononuclear cells from the peripheral blood of a representative Rag1/ mouse transplanted with STAT5-CA;Vav-tTA;TRE-GFP-
shPax5 leukemia and Dox-treated upon leukemia development as indicated. (C) Time course analysis as shown in B for an independent
leukemic recipient mouse. (D) Leukemia burden (proportion of CD19+ cells in the blood) upon Dox treatment (mean 6 SEM; n = 3 mice).
(E) Proportion of CD19+ cells coexpressing IgM upon Dox treatment (mean 6 SEM; n = 3 mice). (F) Flow cytometry of CD19 and CD93
expression on bone marrow cells (top panels) and splenocytes (bottom panels) isolated from representative leukemic Rag1/ mice at
various times during Dox treatment as indicated. The left panels are profiles from untransplanted Rag1/ control mice, indicating
a small population of CD19+ pro-B cells in the bone marrow. (G) Flow cytometry of CD19 and IgM expression as shown in F.
Liu et al.
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Figure 5. Pax5 restoration causes rapid repression of Myc and DNA replication factors. (A) Expression (RNA-seq reads per kilobase per
million mapped reads [RPKM]) of Pax5 in STAT5-CA;Vav-tTA;TRE-GFP-shPax5 leukemia cells harvested from untreated and Dox-
treated leukemic recipient mice compared with normal pre-B cells (mean 6 SEM; n = 3 mice for each group). (B) Western blot of Pax5
and GFP expression in B-ALL cells harvested from duplicate leukemic mice with Dox treatments indicated. Histone H3 is a loading
control. (C) Scatter plot of average RNA-seq differential gene expression in B-ALL cells comparing untreated with 3 d of Dox treatment
(three mice per condition). Genes with significantly increased (red) or decreased (blue) expression in leukemia cells upon Pax5
restoration are indicated (FDR 0.05). Pax5 and Rag1/2 are highlighted. (D,E) RNA-seq expression of Cd19 and Blnk (D) and Rag1/2 (E) in
B-ALL cells as indicated in A. (F) Gene set analysis barcode plot. The RNA-seq differential gene expression data set upon Pax5
restoration in STAT5-CA;Vav-tTA;TRE-GFP-shPax5 leukemia cells in vivo is shown as a shaded rectangle, with genes horizontally
ranked by moderated t statistic; genes up-regulated upon Pax5 restoration are shaded pink (t > 1), and down-regulated genes are shaded
blue (t < 1). Overlaid are a set of previously described genes induced (red bars) or repressed (blue bars) upon the transition from large
cycling pre-B cells to small resting pre-B cells during normal B-cell development in the bone marrow (Hoffmann et al. 2002). Red/blue
traces above/below the bar represent relative enrichment. (G) Heat map of average RNA-seq differential gene expression in STAT5-
CA;Vav-tTA;TRE-GFP-shPax5 leukemia cells harvested from triplicate untreated and Dox-treated leukemic recipient mice (RNA-seq
RPKM is expressed as Z-score, with red and blue indicating up-regulation and down-regulation, respectively). Components of the pre-
BCR complex and the DNA prereplication complex are in bold. (H) Myc mRNA expression as described in A. (I) Cell cycle profiles of
CD45.1CD19+ leukemia cells freshly isolated from untreated and Dox-treated leukemic mice. Cells were stained with DAPI and
analyzed by flow cytometry. Percentages of G0/G1-phase and S/G2/M-phase cells are indicated.
Reversible differentiation block in B-ALL
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leukemia cells (Fig. 5C). The majority (52%) of these
differentially expressed genes was previously identified as
direct Pax5 targets by Bio-ChIP sequencing in pro-B cells
(Revilla-I-Domingo et al. 2012), including well-established
Pax5 target genes such as Cd19 and Blnk (Fig. 5D; Nutt
et al. 1997; Schebesta et al. 2002). Genes insensitive to
Pax5 restoration showed proportionally less (45%) Pax5
binding (P < 1013, Fisher’s exact test). Therefore, despite
differences in the stages of B-cell differentiation exam-
ined by ChIP-seq (chromatin immunoprecipitation [ChIP]
combined with deep sequencing) (pro-B cells) and RNA-
seq (pre-B ALL cells), our RNAi-based approach preferen-
tially identified genes under the direct transcriptional
control of Pax5.
Acute Pax5 restoration causes transcriptional changes
resembling normal B-cell differentiation
Among the genes most sensitive to Pax5 restoration were
the V(D)J recombination activation genes Rag1 and Rag2,
with 15-fold and 38-fold up-regulation, respectively (Fig.
5C,E; Supplemental Table S2). In normal B-cell develop-
ment, Rag1/2 are highly expressed during Igh recombi-
nation in pro-B cells, silenced during the proliferative
expansion of large cycling pre-B cells, and then re-expressed
in small resting pre-B cells to promote Igl/Igk rearrange-
ment (Grawunder et al. 1995). Leukemia cells isolated
from untreated mice had low Rag1/2 expression, in
keeping with their large cycling pre-B stage immunophe-
notype (Fig. 5E), but marked Rag1/2 induction upon Pax5
restoration suggested transition toward the small resting
pre-B-cell stage. Consistent with this, gene set analysis
revealed that global expression changes accompanying
dynamic Pax5 restoration in B-ALL were specifically and
highly correlated (P < 0.0001) with expression changes
that occur at the transition from large cycling to small
resting pre-B cells during normal cell differentiation in
murine bone marrow (Fig. 5F; Supplemental Fig. S4;
Hoffmann et al. 2002). This differentiation step is char-
acterized by proliferative exit (Rolink et al. 1994; Hoffmann
et al. 2002), and, accordingly, genes significantly down-
regulated upon Pax5 restoration were heavily enriched
(40 of the top 75) for critical DNA replication and cell
cycle genes, including those encoding the catalytic sub-
units of the major nuclear DNA polymerases a, d, and e
(Pola1, Pold1, and Pole); DNA prereplication complex
components Cdc6, Cdt1, and Mcm2–7; DNA replisome
components, including Pcna; and nucleotide synthesis
enzymes (Fig. 5G; Supplemental Table S3). Unbiased gene
ontology analysis (Supplemental Table S4) confirmed that
the proliferative transcriptional signature of B-ALL cells
is rapidly suppressed by Pax5 restoration.
Pax5 restoration induces pre-BCR signaling
components and represses Myc
Assembly of a pre-BCR complex following productive Igh
recombination triggers the clonal expansion of large pre-BII
cells. The pre-BCR consists of nascent immunoglobulin
heavy chains associated with the surrogate light chain
(SLC) components Vpreb1/2 and l5 (Igll1) and the signal
transducing subunits Cd79a (Iga) and Cd79b (Igb) (Sup-
plemental Fig. S5A; Herzog et al. 2009). Surprisingly,
genes encoding all pre-BCR components except Vpreb2,
which are among the most highly expressed genes in the
ALL transcriptome (Supplemental Table S5), were signif-
icantly induced following acute re-establishment of Pax5
expression in B-ALL (Fig. 5G; Supplemental Fig. S5B,C).
Furthermore, genes encoding several critical components
of the pre-BCR signal transduction cascade were similarly
induced, including Blnk (SLP-65), Plcg1 (PLC-g1), and the
tyrosine kinases Syk, Btk, Blk, and Lyn (Fig. 5G; Supple-
mental Fig. S5D). Notably, Blnk and Btk also suppress
B-ALL in mice, suggesting that Pax5 loss may promote
B-ALL pathogenesis by attenuating the expression of
multiple tumor suppressor genes (see the Discussion).
Particularly notable among down-regulated genes was
the proto-oncogene Myc (Fig. 5H), ranked 39th by sig-
nificance. Myc stimulates proliferation and inhibits
differentiation by directly modulating the expression of
thousands of genes (Pelengaris et al. 2002). Accordingly,
gene set analysis revealed loss of transcriptional signa-
tures associated with Myc activation upon Pax5 resto-
ration (Supplemental Fig. S6). Myc is required for the
normal proliferative expansion of pre-B cells, and ele-
vated Myc expression is a hallmark of leukemia and
other malignancies (Pelengaris et al. 2002; Habib et al.
2007). Our data indicate that abnormally elevated Myc
expression in B-ALL results primarily from a pre-B-cell
stage differentiation block, which in turn is imposed by
Pax5 loss.
Acute Pax5 restoration disables the leukemia-
initiating capacity of B-ALL cells
DNA content analysis indicated that at least one-third
of STAT5b-CA;Vav-tTA;TRE-GFP-shPax5 B-ALL cells
were cycling in vivo (Fig. 5I). In keeping with coordi-
nated repression of DNA replication and cell cycle
factors upon Pax5 restoration, we observed a rapid de-
crease in the proportion of proliferating ALL cells from
primary leukemias A008 and A024 following acute Dox
treatment in vivo (Fig. 5I; Supplemental Fig. S2I–K). To
test whether the proliferative shutdown caused by brief
Pax5 restoration altered the leukemogenic potential of
ALL cells, we isolated CD19+ A024 leukemia cells from
untreated and Dox-treated primary recipient mice by
FACS and transplanted equal cell numbers into second-
ary recipient mice (Fig. 6A). While leukemia cells
isolated from untreated primary mice produced rapid
leukemia in secondary recipients, tumorigenesis in re-
cipients of leukemia cells from Dox-treated donors was
significantly delayed (Fig. 6B,C). Leukemias eventually
arising in these secondary recipients were GFP+, were
immunophenotypically indistinguishable from primary
leukemias, and regressed upon Dox treatment, suggest-
ing that relapse was driven by renewed Pax5 knockdown
in leukemia cells upon transfer into untreated mice.
Together, these results indicate that brief Pax5 restora-
tion in B-ALL cells in vivo significantly mitigates their
leukemogenic potential.
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PAX5 inhibits the self-renewal of human PAX5 mutant
B-ALL cell lines
To explore the relevance of our findings in human leuke-
mia, we established a system for tet-on-inducible PAX5 re-
expression in three human B-ALL cell lines harboring
PAX5 aberrations that reflect the common pathogenicmu-
tation types. REH cells harbor a PAX5 frameshift mutation
(p.Arg225fs) encoding a protein lacking the C-terminal
transactivation domain (Dorfler and Busslinger 1996),
identical to a recurrent mutation in primary B-ALL
(Mullighan et al. 2007). 697 cells harbor a similar truncat-
ing PAX5 mutation (p.Pro321fs) (Barretina et al. 2012),
whereas NALM-6 cells have a focal, heterozygous deletion
at the PAX5 promoter (Fig. 7A). As a control, we examined
the BCR-ABL1+ lymphoblastic cell line BV173, with nor-
mal PAX5 copy number (Fig. 7A) and sequence (Barretina
et al. 2012).
To facilitate inducible PAX5 re-expression in human
B-ALL cells, we first generated ‘‘tet-on-competent’’ cell lines
by stably expressing the reverse tet transactivator rtTA3
together with the ecotropic receptor and then introduced
retroviral vectors encoding human PAX5 and GFP under
the control of the improved TRE promoter (TRE3G) (Fig.
7B). While enforced expression of PAX5 triggered by Dox
treatment (Fig. 7C) had no major effect on proliferation of
BV173 cells, all threePAX5mutant cell lines showed a rapid
depletion of PAX5-overexpressing cells in competitive pro-
liferation assays (Fig. 7D). Cell cycle analysis indicated
a reduction of cells in S phase that was most pronounced
in 697 cells (Supplemental Fig. S7A,B). In both frameshift
mutant cell lines, PAX5 expression led to a marked re-
duction in cell size reminiscent of the large-to-small pre-B-
cell transition, which was not observed in NALM-6 cells
(Fig. 7E; Supplemental Fig. S7C). Remarkably, in all three
mutant cell lines, PAX5 overexpression triggered clear
shifts in the expression of surface markers associated with
B-cell differentiation. Specifically, enforced PAX5 expres-
sion led to up-regulation of the well-established B-lineage
differentiation marker CD19, while CD38, a highly ex-
pressed marker in normal human bone marrow B-cell
progenitors that is down-regulated in mature B cells in the
blood (Kumagai et al. 1995), was strongly repressed (Fig.
7F; Supplemental Fig. S7D). Intriguingly, PAX5 expression
in both frameshift cell lines also triggered robust expression
of CD10, also known as common ALL antigen (CALLA)
(Fig. 7F). In summary, while the specific phenotype in
response to enforced PAX5 expression varies between
human cell lines, likely due to different background
mutation profiles and culture histories (Barretina et al.
2012), those derived from PAX5 mutant B-ALL remain
addicted to PAX5 hypomorphism.
To identify PAX5-regulated genes in REH cells, we
performed RNA-seq analysis following 2 d of PAX5
induction to enrich for direct PAX5 targets. Overall, 203
genes were up-regulated more than twofold (Supplemen-
tal Fig. S7E), corresponding to 106 genes expressed in our
mouse B-ALL RNA-seq data set. Many genes up-regulated
following Pax5 restoration in our in vivo mouse model
were unaffected in REH cells (Supplemental Fig. S7E),
which could reflect technical differences or biases in-
troduced during long-term culture. Despite this, gene set
analysis demonstrated significant enrichment (P < 0.0005,
roast test) of the 106 REH up-regulated genes among
Pax5-activated genes in our mouse B-ALL model (Supple-
mental Fig. S7F), with 31 of these genes (29%) exceeding
twofold induction in both B-ALL models (Supplemental
Fig. S7E; Supplemental Table S6). Notably, genes com-
monly induced in both species included those encoding
TNFRSF13C/BAFF-R, a major regulator of peripheral B-
cell survival (Mackay et al. 2010); BACH2, a recently
described tumor suppressor in B-ALL (Swaminathan
et al. 2013); and the immunoglobulin l constant region
(Iglc3/IGLC7), consistent with a conserved differentiation
response (Supplemental Fig. S7E).
Figure 6. Pax5 restoration disables the leukemia-initiating capacity of B-ALL cells. (A) Strategy for testing leukemia initiation
properties of B-ALL cells following Pax5 restoration. (B) Peripheral WBC counts from secondary recipient mice 14 d following
transplant with 2 million leukemia cells isolated from primary recipient mice that were treated as indicated. n = 2 mice for each time
point. Horizontal lines indicate average counts. (C) Flow cytometric analysis of leukemia burden (GFP+CD19+ cells) in the blood of
secondary recipient mice 14 d following transplant as described in B.
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Figure 7. PAX5 re-expression is specifically detrimental to PAX5 mutated human B-ALL cell lines. (A) Copy number heat map
showing a focal, heterozygous PAX5 promoter deletion in the NALM-6 cell line (indicated by a horizontal line). PAX5 point mutations
are also indicated. (B) Strategy for generating tet-on-competent human B-ALL cell lines with inducible PAX5 expression. (C) Western
blot of PAX5 expression in B-ALL cell lines following Dox-induced expression of IRES-GFP or PAX5-IRES-GFP as indicated, with
tubulin as a loading control. (D) Time course showing the proportion of GFP+ cells following induction of PAX5-IRES-GFP in the
indicated cell lines relative to matched control IRES-GFP cells. All data were initially normalized to percentage GFP 4 d after Dox
administration. Data are representative of two independent experiments. (E,F) Flow cytometric analysis of cell size/FSC (E) and the cell
surface markers CD19, CD38, and CD10 (F) in GFP (red line) and GFP+ (green line) cells in B-ALL cell lines 3 d after Dox-dependent
induction of PAX5-IRES-GFP. These parameters were unaffected by GFP expression alone (Supplemental Fig. S7C,D).
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Discussion
Mutations in transcription factors and chromatin regula-
tors that govern cell fate decisions are the most striking
finding of recent oncogenomic profiling (Vogelstein et al.
2013); however, most of these driver events remain
functionally unexplored. Importantly, in many cases, it
remains unclear whether these aberrations act predomi-
nantly during tumor initiation (e.g., by locking cells into
progenitor states that are more vulnerable to the acqui-
sition of transforming mutations) or remain essential in
full-blown disease. Loss-of-function mutations in PAX5
and related transcription factors occur in the majority of
cases of B-ALL, a disease characterized by an accumula-
tion of highly proliferative lymphoblasts that fail to
undergo normal differentiation. In this study, we used
a purpose-built mouse model to demonstrate that aber-
rant PAX5 activity specifically acts to enforce a differen-
tiation block in B-ALL, causally linking the hallmark
genetic and phenotypic features of this disease for the
first time. Moreover, we found that PAX5 loss not only is
important for B-ALL pathogenesis but remains critical for
the maintenance of established disease. These properties
of PAX5 are likely in part shared by the other essential
B-lineage transcription factors TCF3 (E2A) and EBF1,
which directly induce PAX5 and are also frequently muta-
tionally inactivated in B-ALL (Kuiper et al. 2007; Mul-
lighan et al. 2007; Nutt and Kee 2007). Hence, our results
define the biological consequences of the predominant
class of tumor suppressor gene mutation in B-ALL.
Restoring Pax5 function in B-ALL driven by its knock-
down triggers a rapid and coordinated in vivo differenti-
ation response that closely mimics the transition of large
cycling pre-B cells to small resting pre-B cells during
normal B lymphopoiesis. Both processes are character-
ized by proliferative exit and concomitant global down-
regulation of genes involved in DNA replication and cell
cycle progression and Rag1/2 up-regulation in preparation
for Igl/Igk gene recombination. In keeping with these
acute molecular changes, sustained Pax5 restoration leads
to a striking immunophenotypicmaturation of antecedent
B-ALL cells, reminiscent of normal B-cell differentiation
and durable tumor regression.
Given the molecular and phenotypic similarities be-
tween Pax5-induced B-ALL differentiation and normal
B-progenitor differentiation, it is likely that partial Pax5
deficiency promotes B-ALL self-renewal by disengaging
mechanisms that normally limit the clonal expansion of
large pre-BII cells during B-cell development. Signaling
from the IL-7 receptor and pre-BCR normally collaborate
to drive a burst of large pre-BII-cell proliferation (Herzog
et al. 2009), and differentiation to the small resting pre-BII
stage is thought to involve shutdown of these pathways.
Notably, Pax5-induced B-ALL differentiation in our model
proceeds despite enforced STAT5 activity, which partially
mimics sustained IL-7 receptor signaling. Similarly, Pax5-
induced B-ALL cell cycle exit occurs despite ongoing
expression of the critical pre-BCR components l5 (Igll1)
and Vpreb1. Together, these findings are consistent with
previous work showing that pre-B-cell expansion can be
curtailed regardless of IL-7 signaling and despite enforced
SLC expression (Milne et al. 2004; van Loo et al. 2007),
suggesting alternative Pax5-dependent mechanisms of
proliferative shutdown. Interestingly, we found that pro-
liferative exit of B-ALL cells upon Pax5 restoration is
associated with significant induction of genes encoding
(1) the core pre-BCR components Vpreb1, l5, Iga, and Igb;
(2) critical pre-BCR signaling proteins, including Blnk,
Syk, and Btk; and (3) known targets of pre-BCR signaling,
including Ikzf3 (Aiolos), Irf4, and Irf8 (Thompson et al.
2007). This suggests that full Pax5 expression may re-
engage pre-BCR-dependent mechanisms that limit clonal
expansion. A tumor-suppressive role for the pre-BCR been
previously proposed inmurine B-ALLmodels (Trageser et al.
2009; Duy et al. 2010) and is also supported by recurrent
IGLL1 and VPREB1 deletions in human B-ALL (Mullighan
et al. 2007; Mangum et al. 2014).
Our results emphasize the importance of Pax5 dosage
in leukemia suppression. B-cell differentiation in Pax5-
null mice is completely blocked at the early pro-B-cell
stage (Urba´nek et al. 1994; Nutt et al. 1997). Surprisingly,
while Pax5 heterozygous mice have apparently normal
B-cell development, they are remarkably susceptible to
B-ALL driven by constitutively active STAT5, and leuke-
mias arising in thesemice retain the wild-type Pax5 allele
(Nutt et al. 1997; Heltemes-Harris et al. 2011). Similarly,
genetic alterations in PAX5 in pediatric B-ALL character-
istically reduce rather than ablate PAX5 transcriptional
activity (Kuiper et al. 2007; Mullighan et al. 2007), and
pre-B leukemias arising in our RNAi-based model express
Pax5 at approximately half of normal levels. These obser-
vations suggest a threshold level of Pax5 activity in B-ALL
that is sufficient to sustain the clonal expansion state
characteristic of normal large pre-B cells but insufficient to
engage differentiation mechanisms that enforce quies-
cence. It is notable that simply doubling the Pax5 dose in
this context drives synchronous leukemia differentiation.
Remarkably, Pax5 hypomorphic B-ALL cells retain the
ability to re-engage a B-lineage differentiation program
despite ongoing expression of activated STAT5 and the
presence of additional oncogenic lesions, providing ra-
tionale for the development of therapeutic approaches
aimed at restoring or mimicking full PAX5 activity in
B-ALL. Approximately 2.5% of B-ALL cases harbor chro-
mosomal rearrangements producing dominant-negative
PAX5 fusion proteins that are, in principle, ‘‘druggable’’
(Mullighan et al. 2007; Nebral et al. 2009; Kawamata et al.
2012). However, the majority of PAX5 aberrations in
B-ALL generally reduce its expression or DNA binding, and
in these cases restoring PAX5 activity is therapeutically
intractable. Despite this, our results suggest that elevated
Myc expression in B-ALL is a critical, albeit indirect,
consequence of the pre-B-cell differentiation arrest
enforced by PAX5 loss. Hence, although MYC is required
for normal B-cell development (Habib et al. 2007), our
data implicate MYC as a rational drug target in PAX5-
deficient B-ALL. Notably, recent studies demonstrate
that the BET bromodomain inhibitor JQ1, which dramat-
ically reduces MYC transcription, has anti-leukemic
activity in primary human B-ALL cell lines and xeno-
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grafts (Ott et al. 2012). Our results suggest that further
interrogation of PAX5-dependent gene expression net-
works in B-ALL may uncover other novel therapeutic
entry points for this disease.
Materials and methods
Additional details are provided in the Supplemental Material.
Fetal liver transduction and reconstitution
Retroviral supernatants were produced by calcium chloride
transfection of 293T cells with plasmids encoding packaging
components and LMP vectors (Dickins et al. 2005) encoding
Pax5 shRNAs. Embryonic day 13.5–14.5 (E13.5–E14.5) fetal
liver cell suspensions were immunomagnetically depleted of
erythryoid cells and transduced using plates treated with retro-
nectin and viral supernatant. Transduced cells were cultured
for 24 h in IMDM supplemented with 10% FCS and cytokines
(100 ng/mL SCF, 10 ng/mL IL-6, 50 ng/mL TPO, 5 ng/mL Flt3)
and injected intravenously into lethally irradiated (twice at
5.5 Gy) recipient mice.
Transgenic mice
The TREtight-GFP-Pax5.437 and TREtight-GFP-Ren.713 trans-
genes were targeted to the type I collagen (Col1a1) locus using
previously described protocols (Premsrirut et al. 2011). Genotyp-
ing details are provided in the Supplemental Material. Dox
(Sigma-Aldrich) was administered in the diet at 600 mg per
kilogram of food (Specialty Feeds). All mouse experiments were
approved by the Walter and Eliza Hall Institute Animal Ethics
Committee.
Blood and flow cytometry analysis
Mice were monitored for signs of leukemia, including loss of
activity or weight, breathing difficulty, enlarged lymph nodes,
and palpable splenomegaly. Blood was collected from the retro-
orbital plexus, mandible, or tail vein, and parameters were
measured with an Advia 2120 hematological analyzer (Bayer).
Single-cell suspensions were prepared from bonemarrow, spleen,
lymph nodes, or peripheral blood and treated with red cell lysis
buffer. FACS antibody details are provided in the Supplemental
Material. Stained cells were analyzed or sorted by flow cytom-
etry (LSR II or LSRFortessa, BD Biosciences). FACS data were
analyzed with FlowJo software (Tree Star).
Leukemia transplantation and human B-ALL cell line culture
Primary mouse leukemia cells were transplanted intrave-
nously into immunocompromised CD45Ly5.1Rag1/ recipient
mice. Approximately 2 3 106 primary or secondary leukemia
cells were transplanted. Transplant recipients generally de-
veloped overt leukemia 2–3 wk after transplantation. The
human B-ALL cell line culture is described in the Supplemental
Material.
DNA content analysis
Following staining with antibodies described above, cells were
permeabilized and fixed using the Cytofix/Cytoperm kit (BD
Biosciences). Cells were then stained with DAPI (49,6-diamidino-
2-phenylindole dihydrochloride) (Sigma-Aldrich) and analyzed
for DNA content by flow cytometry.
Western blotting
Lysates prepared from either cultured cell lines or ex vivo sorted
cells were Western-blotted with anti-Pax5 antibody 1H9, anti-
GFP antibody A6455 (Invitrogen), and anti-acetyl-Histone H3
antibody 06-599 (Millipore).
RNA-seq, bioinformatics, and statistical analysis
Total RNAwas extracted using the RNeasy Plus minikit (Qiagen)
and profiled on Illumina HiSeq 2000 sequencers. Reads were
mapped to themouse or human genomes using subread (Liao et al.
2013), summarized using featureCounts (Liao et al. 2014), and
analyzed for differential expression using voom (Law et al. 2014).
Enrichment analysis used roast (Wu et al. 2010). Details are
described in the Supplemental Material. RNA-seq data are avail-
able at the Gene Expression Omnibus (GEO) through accession
numbers GSE52868, GSE52870, and GSE57480.
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